Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 4 hours ago
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
about 4 hours ago
Kyverna Therapeutics has officially started a rolling submission to the FDA for...
FDA Commissioner Marty Makary to resign, capping turbulent tenure: report
about 4 hours ago
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief...
Charles River debuts AI diagnostic tool to cut down pathology timelines
about 8 hours ago
Charles River is rolling out an artificial intelligence-backed digital pathology platform with...
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
about 9 hours ago
If any proof was needed that big money is still available for...
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
about 10 hours ago
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure...
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
about 11 hours ago
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in...
Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test
about 13 hours ago
Roche has secured a European CE mark for its second Alzheimer’s test...
Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
about 14 hours ago
Bayer has removed a protein therapeutic for hypertension and a treatment for...
Blood-based approach could detect early heart, kidney disease, study finds
about 15 hours ago
Scientists know that damage to microscopic blood vessels can provide an early...
Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
about 16 hours ago
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has...
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed
about 18 hours ago
Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying...
Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
1 day ago
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top...